Linde Plc Q3 FY2026 earnings call

• Financial Record: Set quarterly records for sales ($9.4B), operating profit ($2.8B), and EPS ($4.59), though operating margin excluding pass-through was flat.
• Restructuring Actions: Recorded a $425 million restructuring charge to align costs with market conditions; Link Care moved to 'Global Others' for better transparency and strategic evaluation.
• Market Performance: Electronics led growth at 15%, driven by strong demand in the U.S., Korea, and China. Chemicals and Energy grew 12% due to volume and pricing actions. Healthcare grew 2% overall, but mid-single digits excluding Link Care.
• Geographic Trends: Volume growth concentrated in key geographies (U.S., China, India) and end markets. Europe remains stagnant with no clear catalyst for recovery despite better comps. China's steel production declined, but electronics surged 17%.
• Pricing & Inflation: Prices increased 3% globally, with stronger acceleration in the Americas due to energy and distribution cost recoveries. Management is actively tracking inflationary momentum.
• Operational Discipline: Emphasis on continuous improvement, accountability, and capital allocation. Balance sheet health provides optionality amidst macro uncertainty.

Consolidated sales reached $9.4 billion, with an operating profit of $2.8 billion and EPS of $4.59. While specific segment revenue contributions were not detailed in absolute terms for all divisions, the Americas segment is highlighted as having the highest inflation and pricing power (approx. 6% price increase, including cost recovery). The Engineering segment saw growth from higher third-party plant sales. The Link Care business, moved to 'Global Others,' continues to weigh on results but is undergoing restructuring.

• Q4 2026 EPS: Guided between $4.40 and $4.50, representing 5% to 7% year-over-year growth.
• Full-Year 2026 EPS: Maintained guidance range of $17.82 to $17.92.
• FX Impact: Full-year FX benefit revised upward slightly from 1% to 2% (attributed to rounding).
• Assumptions: No economic improvement assumed; cautious view on near-term profitability improvements for Link Care.

• European Industrial Malaise: Structural cost disadvantages, high energy prices, and lack of consistent industrial policy framework continue to suppress growth in Europe.
• Link Care Underperformance: The business remains a headwind to overall results, requiring significant operational improvements and strategic evaluation.
• Inflationary Pressures: Accelerating energy and distribution costs, particularly in North America, require ongoing price recovery actions that may dilute margins if not fully offset by permanent pricing.
• China Domestic Demand: Weak domestic consumption in China poses a risk, with growth currently reliant on exports and specific sectors like electronics.

Q: Analyst asked about the progress of the $8 billion sale-of-gas project backlog and its impact on engineering sales growth in 2027. / A: CEO stated the backlog remains close to $8 billion, with expectations to start up projects totaling around $1 billion in the current quarter. He expressed confidence in hitting the target depending on customer timing. Regarding the sale-of-plant backlog (under $3 billion), he expects it to grow over the next year, with more specific guidance on the business outlook to be provided in February 2027.

Q: CFO addressed why COGS rose 13% YoY while sales/volume only rose 3%, implying a 10% per-unit cost increase. / A: CFO explained that 1% was FX impact and 1% was cost pass-through. Additionally, strong performance in the hydrogen business (Hyco) drove up variable costs. He noted that accelerated energy and distribution cost pressures in North America required incremental recovery, which looked more pronounced now that Link Care was moved out of the Americas segment denominator. These costs are expected to normalize in Q4.

Q: Analyst asked how the severance portion of the restructuring will impact savings and efficiency in 2027 compared to normal productivity gains. / A: CFO clarified that severance paybacks typically occur within one to two years, with this charge closer to the two-year end. Benefits start in Q4 2026, with full run-rate benefits expected in the second half of 2027. He confirmed these episodic restructuring savings are additive to the ongoing, embedded productivity gains.

Q: Analyst questioned the deceleration in Q4 EPS guidance (7% growth vs. 9% in Q3) and what it implies for 2027. / A: CFO attributed the sequential decline to three factors: 1% FX headwind from a strengthening dollar, ~1% reduction from normalized equity income after a Q3 spike, and seasonality/caution regarding economic conditions. He emphasized that the company is taking a guarded view on the economy and Link Care actions, aiming to exceed the range but leaving the full-year guide intact due to lack of bullish signals.

Q: CEO discussed the outlook for European volumes and China's domestic demand, noting Europe showed slight improvement but China's steel production fell. / A: CEO stated Europe remains flat underlying, with no catalyst for growth due to lack of industrial policy and high energy costs. In China, steel production dropped 2.5% due to government curtailment orders, and chemicals were flat. However, electronics industrial production surged 17%. He expressed concern over weak domestic demand in China, suggesting sustained improvement requires a pickup in consumption alongside export strength.